# Nuvation Bio Inc. (NUVB) — capital_raise/public_offering [announced]
Source: SEC API (secapi.ai) · situation sit_b14b0e58859426320985 · retrieved 2026-08-12T07:39:45.461Z

## Overview
Nuvation Bio is a global oncology company focused on developing therapies for cancer treatment, with a diverse pipeline including taletrectinib (IBTROZI), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.

Nuvation Bio completed a public offering of 0.75% Convertible Senior Notes in July 2026, generating approximately $279.1 million in net proceeds after fees and reimbursements. Concurrently, the company entered into capped call transactions at a cap price of $10.4580 per share, representing an 80.0% premium over the last reported sale price of $5.81 per share, to reduce dilution to shareholders.

## Terms
- Deal value: $279.1M · Consideration: cash · Premium: 80.0% · Price/share: $10.458

## Key dates
- Announced 2026-08-06

## Timeline
- 2026-08-06 · 8-K (0001193125-26-336751): 8-K - Nuvation Bio Inc. — *Nuvation Bio is a global oncology company focused on developing therapies for cancer treatment, with a diverse pipeline including taletrectinib (IBTROZI), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.* Nuvation Bio completed a public offering of 0.75% Convertible Senior Notes in July 2026, generating approximately $279.1 million in net proceeds after fees and reimbursements. Concurrently, the company entered into capped call transactions at a cap price of $10.4580 per share, representing an 80.0% premium over the last reported sale price of $5.81 per share, to reduce dilution to shareholders.
  https://www.sec.gov/Archives/edgar/data/1811063/0001193125-26-336751.txt

## Citations
- 0001193125-26-336751 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526336751